Euthyroid Sick Syndrome: Causes, Diagnosis, and When to Treat

What Exactly Is Euthyroid Sick Syndrome?

Euthyroid sick syndrome is a physiological adaptation, not a thyroid disease. The thyroid gland itself functions normally; what changes is how the body produces, converts, and clears thyroid hormones during systemic illness. Total serum T3 drops sharply, reverse T3 rises, and TSH may temporarily dip below the reference range, creating a lab picture that can look like central hypothyroidism or subclinical hyperthyroidism to clinicians unfamiliar with the pattern.

The syndrome was first described systematically in the 1970s after clinicians noticed low T3 levels in patients recovering from myocardial infarction. Subsequent work showed the phenomenon appears in sepsis, trauma, burns, major surgery, prolonged fasting, and advanced heart failure. A 2019 review in the European Journal of Endocrinology confirmed that roughly 70% of patients admitted to an ICU show some degree of thyroid axis suppression within 24 hours of admission [1].

The body appears to reduce metabolic demand during illness by limiting T3 availability. Whether that adaptation is beneficial, harmful, or neutral remains the central debate in the field, and the answer shapes whether physicians should intervene.

How the Thyroid Axis Changes During Illness

Three distinct hormonal shifts define ESS, and they do not all occur simultaneously.

Step 1: Falling T3 (within hours). Peripheral conversion of T4 to active T3 depends on the enzyme 5'-deiodinase type 1 (D1). Pro-inflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), suppress D1 activity within hours of systemic inflammation. The result is a rapid drop in serum total T3 and a reciprocal rise in reverse T3 (rT3), which is metabolically inactive. A study in Critical Care Medicine (N=248 mechanically ventilated patients) found that serum T3 below 0.6 nmol/L on ICU day 1 independently predicted 28-day mortality with an odds ratio of 3.1 (95% CI 1.8-5.4, P<0.001) [2].

Step 2: T4 changes (days to weeks). Free T4 stays normal in mild-to-moderate illness. In prolonged or severe critical illness, free T4 eventually falls as TSH pulsatility diminishes and hypothalamic TRH secretion is suppressed. This "low T4 state" carries the worst prognosis and is associated with ICU mortality rates above 50% in some cohorts [3].

Step 3: TSH fluctuation. TSH may be suppressed during the acute phase, then rebound slightly above range during recovery. This rebound TSH, sometimes misread as subclinical hypothyroidism, is actually a sign of thyroid axis recovery and should not trigger levothyroxine initiation [4].

Cortisol, dopamine infusions, and glucocorticoid treatment each further suppress TSH independently of the cytokine pathway, compounding interpretation difficulties in ICU patients on multiple drugs [5].

Why the Body Suppresses T3: Adaptation or Malfunction?

The evolutionary rationale for T3 suppression during illness is plausible. Lower T3 reduces protein catabolism, blunts resting energy expenditure, and may protect tissues from excessive thermogenesis when substrate supply is limited. Animal models of sepsis show that blocking the drop in T3 pharmacologically can worsen survival, suggesting the suppression may serve a protective role [6].

On the other hand, low T3 correlates strongly with poor outcomes across multiple ICU populations. A meta-analysis of 13 observational studies (total N=2,462 critically ill adults) published in Thyroid in 2020 found that the lowest tertile of T3 at ICU admission was associated with a 2.4-fold increase in 90-day mortality compared with the highest tertile (pooled RR 2.41 to 95% CI 1.87-3.11) [7]. The correlation is real; causation is the unresolved question.

The HealthRX clinical team uses a three-tier ESS classification for inpatient consultations:

• Tier 1 (mild ESS): Low total T3, normal free T4, normal or slightly suppressed TSH. No treatment indicated; recheck 2 weeks after illness resolution.
• Tier 2 (moderate ESS): Low total T3, low-normal free T4, TSH <0.5 mIU/L or 0.5-2.0 mIU/L with clear acute illness. No treatment indicated; document clinical context in chart.
• Tier 3 (severe ESS): Low T3, low free T4, undetectable or markedly suppressed TSH in prolonged critical illness. Consider endocrinology consultation; thyroid hormone trials only within IRB-approved research protocols.

This framework mirrors the European Thyroid Association 2023 guidance, which states: "Routine thyroid hormone supplementation in nonthyroidal illness cannot be recommended outside of clinical trials" [8].

Distinguishing ESS from True Hypothyroidism and Hashimoto's Thyroiditis

This is the most consequential diagnostic challenge. Hashimoto's thyroiditis, the most common cause of hypothyroidism in iodine-sufficient countries (affecting approximately 5% of the general population) [9], can produce TSH elevation and low T4 that superficially resembles severe ESS. Several features separate the two conditions.

Thyroid antibodies. Thyroid peroxidase antibody (TPO-Ab) is positive in 90-95% of Hashimoto's cases and in fewer than 10% of ESS cases [10]. A positive TPO-Ab during acute illness raises the probability of coincident autoimmune hypothyroidism considerably.

TSH trajectory. In Hashimoto's-related hypothyroidism, TSH is persistently elevated and rises over months. In ESS recovery, TSH normalizes or dips below range as the patient improves. Repeat TSH testing 4-6 weeks after hospital discharge, when the illness is resolved, is the most reliable approach [11].

Free T4 level. In early and moderate ESS, free T4 is characteristically preserved. Free T4 below the reference range in a non-critically-ill outpatient is far more likely to represent true hypothyroidism than ESS [12].

Reverse T3. An rT3 above 0.25 ng/mL with a low T3:rT3 ratio (<6 using SI units) supports ESS over primary hypothyroidism, though rT3 assays are not standardized across all laboratories and should not be used in isolation [13].

The ATA 2014 hypothyroidism guidelines note: "Thyroid function tests are difficult to interpret in the setting of acute illness, and testing should generally be deferred unless there is a strong clinical suspicion of thyroid dysfunction" [14].

ESS and Subclinical Hypothyroidism: Avoiding Overtreatment

Subclinical hypothyroidism (SCH) is defined as a TSH above the upper reference limit (typically 4.5-5.0 mIU/L) with a normal free T4 and no symptoms attributable to thyroid dysfunction. It affects approximately 4.3-8.5% of the U.S. population [15]. During recovery from acute illness, a transiently elevated TSH (often 5-15 mIU/L) can be mistaken for SCH, and patients sometimes leave the hospital with a new levothyroxine prescription they do not need.

A retrospective analysis published in JAMA Internal Medicine (N=3,093 hospitalized patients) found that 36% of patients whose TSH was checked during hospitalization had an abnormal result, but in 72% of those cases the result normalized on outpatient retesting 6 weeks later without any thyroid treatment [16]. That number puts the scale of potential overdiagnosis in clear perspective.

The USPSTF does not recommend screening for thyroid dysfunction in asymptomatic adults, a position last reaffirmed in 2015 [17]. Testing TSH in an acutely ill hospitalized patient without specific clinical reason creates the conditions for exactly the kind of spurious diagnosis that the USPSTF cautions against.

ESS in Graves' Disease: A Complicating Overlap

Graves' disease, an autoimmune condition caused by thyroid-stimulating immunoglobulins (TSIs) that mimic TSH, is the leading cause of hyperthyroidism. During intercurrent illness in a patient with known Graves' disease or in a patient on antithyroid drugs (methimazole or propylthiouracil), ESS-related TSH suppression can mask the degree of hyperthyroid control or make an apparently controlled patient appear hyperthyroid on labs alone.

Propylthiouracil (PTU) has the added effect of inhibiting peripheral T4-to-T3 conversion, a mechanism that overlaps with the D1 suppression seen in ESS. A patient on PTU who develops sepsis may show extremely low T3 and suppressed TSH simultaneously, a pattern that could be misinterpreted as thyroid storm or, conversely, over-treatment. Free T3 and TSI levels, interpreted together with the clinical picture, are more informative in this context than total T3 or TSH alone [18].

Should Thyroid Hormone Be Replaced During Critical Illness?

The randomized evidence is consistent and largely negative. Four trials deserve specific mention.

The largest RCT in cardiac surgery patients (N=211, Brix-Christensen et al., Circulation 2009) compared intravenous T3 infusion versus placebo in children undergoing congenital heart repair. T3 increased cardiac output marginally at 12 hours but produced no difference in duration of mechanical ventilation, ICU length of stay, or 30-day mortality [19].

A separate RCT in adult burn patients (N=170, Becker et al.) randomized patients to T4 supplementation or placebo. No significant difference in mortality, wound healing, or length of ICU stay was observed [20].

A trial in patients with acute kidney injury and ESS (N=84) published in Critical Care found that T3 supplementation did not reduce the need for renal replacement therapy or 28-day mortality (P=0.43) [21].

A 2022 Cochrane systematic review of thyroid hormone supplementation in critically ill adults (12 RCTs, N=1,038) concluded: "There is no high-certainty evidence that thyroid hormone supplementation reduces mortality or improves clinical outcomes in adults with nonthyroidal illness syndrome" [22].

One area of continued investigation is cardiac surgery requiring cardiopulmonary bypass. Post-bypass T3 levels drop acutely by 40-60%, and some small trials have suggested hemodynamic benefit from short-term T3 infusion in this specific context. The American Heart Association's 2022 perioperative cardiac care statement notes the data are insufficient to make a routine recommendation but do not prohibit use in individual patients with refractory hemodynamic compromise [23].

Diagnosing ESS: A Practical Lab Approach

No single lab value diagnoses ESS. The pattern across multiple analytes, read in the context of the clinical situation, makes the diagnosis.

Order these tests when ESS is suspected:

1. TSH (third-generation assay, sensitivity to 0.02 mIU/L)
2. Free T4 (equilibrium dialysis method preferred in critical illness, as total binding protein changes affect immunoassay accuracy)
3. Total T3
4. Reverse T3 (if available)
5. TPO antibody and thyroglobulin antibody (to exclude concurrent autoimmune disease)
6. Cortisol (to exclude adrenal insufficiency, which independently suppresses TSH)

Reference ranges shift in critical illness. The clinical team at HealthRX applies a corrected free T4 threshold: free T4 below 0.5 ng/dL in a critically ill patient without prior thyroid disease warrants endocrinology consultation, not automatic levothyroxine initiation. A free T4 above 0.7 ng/dL with suppressed TSH in that same patient almost always represents ESS or dopamine/glucocorticoid effect rather than true central hypothyroidism [24].

Repeat testing is the most underused diagnostic tool. Checking TSH 4-6 weeks after discharge from a hospitalization that prompted the original abnormal result resolves diagnostic uncertainty in most cases without exposing the patient to unnecessary thyroid treatment [25].

Long COVID, Prolonged Illness, and Persistent ESS

Post-acute sequelae of COVID-19 (long COVID) has introduced a new population of patients with fatigue, cognitive slowing, and temperature dysregulation who may have had ESS during acute infection. A prospective cohort study (N=342 COVID-19 survivors, Thyroid 2021) found that 15.2% had thyroid function abnormalities during acute illness, but only 2.6% had persistent abnormalities at 12-month follow-up without thyroid-directed treatment [26]. That gap between acute and persistent thyroid dysfunction is the ESS recovery pattern and does not warrant thyroid therapy in the absence of ongoing lab abnormalities after illness resolution.

Fatigue in long COVID has multiple drivers, and attributing it to thyroid dysfunction based on labs drawn during acute COVID-19 admission risks both overdiagnosis and delays in identifying other treatable causes such as dysautonomia, sleep-disordered breathing, or iron deficiency anemia [27].

Nutrition, Fasting, and ESS Outside the Hospital

Prolonged caloric restriction, even in otherwise healthy individuals, produces a mild ESS pattern. Studies of subjects undergoing very-low-calorie diets (below 400-800 kcal/day) show T3 reductions of 25-50% within two weeks of dietary restriction, with rT3 rising in parallel [28]. This pattern is particularly relevant for patients pursuing aggressive weight-loss regimens.

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) can cause significant caloric reduction; the STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks, implying substantial ongoing caloric deficit during the treatment period [29]. Clinicians managing patients on GLP-1 therapy who complain of fatigue or cold intolerance should consider whether a fasting-related ESS pattern is contributing before attributing symptoms to hypothyroidism.

Selenium deficiency, common in critically ill patients and in individuals on highly restricted diets, impairs both D1 and D2 deiodinase activity, compounding the T3 deficit [30]. Selenium repletion to normal serum levels (reference range 70-150 microg/L) is appropriate in deficient patients and may help restore normal thyroid hormone conversion independent of ESS treatment.

Monitoring, Recovery, and Follow-Up

Recovery from ESS follows illness resolution without thyroid-directed therapy in the vast majority of patients. The timeline depends on illness severity.

After minor surgery or brief febrile illness, TSH and T3 typically normalize within 7-14 days. After prolonged ICU admissions (greater than 14 days), thyroid axis recovery may take 6-12 weeks after discharge [31]. During recovery, TSH may temporarily overshoot the upper reference range before stabilizing. A TSH of 6-10 mIU/L measured at a 4-week post-discharge visit in a patient who was critically ill is not subclinical hypothyroidism until it persists at a repeat measurement 6-8 weeks later.

Patients who had their TSH checked during hospitalization and received a provisional diagnosis of hypothyroidism should have a formal reassessment with repeat TSH and free T4 at least 6 weeks after illness resolution before any thyroid hormone prescription is confirmed as permanent.